Boehringer

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

Retrieved on: 
Mercredi, mai 22, 2024
Partnership, Patient, Discovery, CRM, Boehringer Ingelheim, Cancer, EUR, Death, Acquisition, Apoptosis, Boehringer, Pharmaceutical industry

Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership.

Key Points: 
  • Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership.
  • Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs.
  • A new preclinical program will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting1 anti-PD1/cytokine platform via an asset acquisition.
  • Cancer accounts for nearly 10 million deaths and for many cancer patients there are no or only limited treatment options.

Boehringer Ingelheim expands access to adalimumab-adbm injection, the company's biosimilar to Humira®

Retrieved on: 
Lundi, mai 13, 2024
Adalimumab, Partnership, Patient, Access, Purple, Pharmacy, Boehringer Ingelheim, Senior, Boehringer, Fine chemical

We're committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options."

Key Points: 
  • We're committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options."
  • Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent.
  • Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo® (adalimumab-adbm) injection and Adalimumab-adbm.
  • "We are pleased to be working with Boehringer Ingelheim to bring adalimumab-adbm to more patients.

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Retrieved on: 
Mardi, mai 7, 2024
Hyperglycemia, Insulin, DOI, Boehringer Ingelheim, Pet, Veterinarian, Health, Animal, Research, SJM, Diabetes, Health Canada, Trigger, Vaccine, Farmer, Needle, Cat, Human, Veterinary medicine, Livestock, Food, Diagnosis, Boehringer, Diabetes in cats, Euthanasia, Horse, Report

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.

Key Points: 
  • SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.
  • SENVELGO™ is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus.
  • Pet owners can give the once-daily liquid oral solution with a small amount of food or directly into the cat's mouth.
  • Dr. Walt Ingwersen, Technical Services Veterinarian with Boehringer Ingelheim Canada, said SENVELGO™ revolutionizes the treatment and management of feline diabetes in newly diagnosed cats.

Boehringer Ingelheim Unveils New R&D Laboratory in St. Joseph, Mo., Pioneering the Future of Animal Health Products

Retrieved on: 
Vendredi, mai 3, 2024
Health, Animal, Heart, Boehringer, Horse, Research, Livestock, Boehringer Ingelheim, Corridor, Fine chemical

ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.

Key Points: 
  • ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.
  • This state-of-the-art facility is set to revolutionize the development of future products, including biotherapeutics.
  • This location is primarily dedicated to the product development and production of animal health products for livestock and horses.
  • "Boehringer Ingelheim is not just a global leader in animal health – they are a part of the fabric of our community," said Kim Young, President KC Animal Health Corridor.

Less than half of veterinary professionals feel their profession is appreciated

Retrieved on: 
Jeudi, avril 25, 2024
Corporate headquarters, Food safety, Agriculture, Poultry, Head, Boehringer Ingelheim, Risk, Pet, AVMA, Veterinarian, Health, Animal, Infection, Horse, Research, Vaccine, Farmer, Cat, Human, Mental health, Livestock, Interface (computing), Pig, Dog, Boehringer, Organization, Veterinary medicine

World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.

Key Points: 
  • World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
  • Veterinary associations and Boehringer Ingelheim unite to help address this issue—starting with showcasing often-unseen aspects of the veterinary profession.
  • A main finding of the study is that only 49% of veterinarians feel that the veterinary profession in general is appreciated.
  • It truly is a vocation to aspire to.”
    Perceived levels of appreciation for the veterinary profession were relatively consistent across key types of veterinary teams — with only 48% of pet-focused (cats and dogs), 55% of livestock and 42% of equine veterinary professionals reporting that their profession was appreciated.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Retrieved on: 
Mardi, avril 16, 2024
Science, Corporate headquarters, FDA, Health equity, Investment, Liver disease, Growth, EUR, Vaccine, Tick, Biomass, DSM-IV codes, Medicine, Finance, CRM, Chronic kidney disease, Executive officer, Heart failure, Paris Agreement, Research and development, Dog, Capital expenditure, Flea, MASH, Idiopathic pulmonary fibrosis, Coccidioides immitis, Stroke, Acceleration, Pet, Health, Diabetes, Artificial intelligence, Mental health, EMA, Notifiable disease, Cancer, Boehringer Ingelheim, Phase II, Pharma, Cat, Environment, Patient, Conditional sentence, Boehringer, Pharmaceutical industry

Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.

Key Points: 
  • Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.
  • “I am excited to see how balanced and healthy our pipeline looks today,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
  • To support the company’s growth, Boehringer announced a 5-year, EUR 7 billion capital investment plan last year.
  • For 2024, Boehringer Ingelheim expects a slight year-on-year increase in revenues on a comparable basis, adjusted for currency and extraordinary effects.

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Retrieved on: 
Jeudi, mai 2, 2024
Technology, Men, LGBTQ+, Professional Services, DEI (Diversity, Equity and Inclusion), Consumer, Clinical Trials, Diabetes, Health, Apps, Applications, Generation Z, Generation X, Other Consumer, Mobile, Wireless, Baby Boomers, Women, Pharmaceutical, Boehringer Ingelheim, Heart, Overweight, Death, Partnership, Research, Medicine, Environment, Obesity, Senior, Patient, Multimedia, Boehringer, Clinical trial, Pharmacy, Pharmaceutical industry

Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.

Key Points: 
  • Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
  • View the full release here: https://www.businesswire.com/news/home/20240502134064/en/
    Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes.
  • “Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” said Ramita Tandon, Chief Clinical Trials Officer at Walgreens.
  • “Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. “By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials.

Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease

Retrieved on: 
Lundi, avril 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, USD, Cirrhosis, Genomics, CLD, Liver disease, Boehringer Ingelheim, Chronic liver disease, Machine learning, The Gentle Touch, RNA, Partnership, Liver regeneration, Senior, Patient, Liver failure, DSM-IV codes, Disease, CRM, Boehringer, MASH, Outsourcing, Copper

Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Key Points: 
  • Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
  • Boehringer Ingelheim aims to develop new treatments modulating innovative regenerative targets with the potential to enhance the liver’s self-repair capabilities to prevent or reverse disease progression.
  • It builds on Ochre Bio’s leading capabilities to leverage human data and disease models to accelerate the discovery and validation of novel liver disease targets.
  • “Ochre Bio brings to the table unique and exciting capabilities in liver disease research.

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need

Retrieved on: 
Vendredi, mars 15, 2024
Parasitism, Health, DSM-IV codes, Moxidectin, Coccidioides immitis, Boehringer Ingelheim, Tablet, Tick, Diarrhea, Dog, Lethargy, Boehringer, Breeding, Pet, Vomiting, Animal, Pharmaceutical industry

The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.

Key Points: 
  • The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
  • The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms.
  • Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.

Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

Retrieved on: 
Jeudi, février 22, 2024
Drug development, Patient, AML, Boehringer, Risk, Pharmaceutical industry

Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML).

Key Points: 
  • Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML).
  • “We in-licensed volasertib because of its robust clinical experience in Boehringer Ingelheim’s expansive Phases 1-3 program and our PPMP data that distinguished predicted volasertib-responders from predicted non-responders based on samples from patients with AML.
  • We therefore believe that PPMP will focus volasertib’s development on clinically responding patients, boost its clinical response rate and enhance patient outcomes,” continued Dr. Bock.
  • This analysis suggests that standardizing best supportive care and introducing body surface area-based dosing are likely to enhance patient responses and tolerability.